Targeting of drugs and nanoparticles to tumors

Journal of Cell Biology

Volumn 188, Issue 6, 2010, Pages 759-768

  Ruoslahti, Erkki ^a,b   Bhatia, Sangeeta N ^c,d,e   Sailor, Michael J ^f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BURNHAM INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d USA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; ARGINYLGLYCYLASPARTIC ACID; ASPARAGINYLGLYCYLARGININE; CD51 ANTIGEN; DOXORUBICIN; ENDOSIALIN; F3 PEPTIDE; FIBRIN; FIBRONECTIN; FOLIC ACID; GOLD NANOPARTICLE; MOLECULAR MARKER; NANOCARRIER; NANOCOATING; NANOPARTICLE; NANOROD; NUCLEOLIN; PACLITAXEL; PEPTIDE DERIVATIVE; PLECTIN; POLYPEPTIDE ANTIBIOTIC AGENT; TRASTUZUMAB; TRIPEPTIDE; TUMOR MARKER; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; BINDING AFFINITY; BLOOD VESSEL; CANCER INHIBITION; CELL TYPE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; GENE VECTOR; HUMAN; MOLECULAR DOCKING; MOLECULE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SCREENING; TUMOR VASCULARIZATION;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949762340     PISSN: 00219525     EISSN: 00219525     Source Type: Journal    
DOI: 10.1083/jcb.200910104     Document Type: Review

References (101)

1. Abe, K., M. Shoji, J. Chen, A. Bierhaus, I. Danave, C. Micko, K. Casper, D.L. Dillehay, P.P. Nawroth, and F.R. Rickles. 1999. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl. Acad. Sci. USA. 96:8663-8668. doi:10.1073/ pnas.96.15.8663
2. Alitalo, K., and P. Carmeliet. 2002. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 1:219-227. doi:10.1016/ S1535-6108(02)00051-X
3. Arap, W., R. Pasqualini, and E. Ruoslahti. 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:377-380. doi:10.1126/science.279.5349.377
4. Arap, W., W. Haedicke, M. Bernasconi, R. Kain, D. Rajotte, S. Krajewski, H.M. Ellerby, D.E. Bredesen, R. Pasqualini, and E. Ruoslahti. 2002. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. USA. 99:1527-1531. doi:10.1073/pnas.241655998
5. Bartlett, D.W., H. Su, I.J. Hildebrandt, W.A. Weber, and M.E. Davis. 2007. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA. 104:15549-15554. doi:10.1073/pnas .0707461104
6. Bieker, R., T. Kessler, C. Schwöppe, T. Padró, T. Persigehl, C. Bremer, J. Dreischalück, A. Kolkmeyer, W. Heindel, R.M. Mesters, and W.E. Berdel. 2009. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood. 113:5019-5027. doi:10.1182/blood-2008-04-150318
7. Bonnet, H., O. Filhol, I. Truchet, P. Brethenou, C. Cochet, F. Amalric, and G. Bouche. 1996. Fibroblast growth factor-2 binds to the regulatory beta subunit of CK2 and directly stimulates CK2 activity toward nucleolin. J. Biol. Chem. 271:24781-24787. doi:10.1074/jbc.271.40.24781
8. Borer, R.A., C.F. Lehner, H.M. Eppenberger, and E.A. Nigg. 1989. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 56:379-390. doi:10.1016/0092-8674(89)90241-9
9. Borgia, B., C. Roesli, T. Fugmann, C. Schliemann, M. Cesca, D. Neri, and R. Giavazzi. 2010. A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Res. 70:309-318. doi:10.1158/0008- 5472.CAN-09-2939
10. Brooks, P.C., R.A.F. Clark, and D.A. Cheresh. 1994. Requirement of vascular integrin α v β 3 for angiogenesis. Science. 264:569-571. doi:10.1126/ science.7512751
11. Carson-Walter, E.B., D.N. Watkins, A. Nanda, B. Vogelstein, K.W. Kinzler, and B. St Croix. 2001. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 61:6649-6655.
12. Chang, D.K., C.Y. Chiu, S.Y. Kuo, W.C. Lin, A. Lo, Y.P. Wang, P.C. Li, and H.C. Wu. 2009. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem. 284:12905-12916. doi:10.1074/ jbc.M900280200
13. Choi, H.S., W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi, and J.V. Frangioni. 2007. Renal clearance of quantum dots. Nat. Biotechnol. 25:1165-1170. doi:10.1038/nbt1340
14. Christian, S., H. Ahorn, A. Koehler, F. Eisenhaber, H.P. Rodi, P. Garin-Chesa, J.E. Park, W.J. Rettig, and M.C. Lenter. 2001. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J. Biol. Chem. 276:7408-7414. doi:10.1074/jbc .M009604200
15. Christian, S., J. Pilch, M.E. Akerman, K. Porkka, P. Laakkonen, and E. Ruoslahti. 2003. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 163:871-878. doi:10.1083/jcb.200304132
16. Curnis, F., A. Gasparri, A. Sacchi, R. Longhi, and A. Corti. 2004. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 64:565-571. doi:10.1158/0008-5472. CAN-03-1753
17. Curnis, F., A. Sacchi, A. Gasparri, R. Longhi, A. Bachi, C. Doglioni, C. Bordignon, C. Traversari, G.P. Rizzardi, and A. Corti. 2008. Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res. 68:7073-7082. doi:10.1158/0008-5472.CAN-08-1272
18. Desgrosellier, J.S., and D.A. Cheresh. 2010. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer. 10:9-22. doi:10.1038/nrc2748
19. Drecoll, E., F.C. Gaertner, M. Miederer, B. Blechert, M. Vallon, J.M. Müller, A. Alke, C. Seidl, F. Bruchertseifer, A. Morgenstern, et al. 2009. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One. 4:e5715. doi:10.1371/journal.pone.0005715
20. Dvorak, H.F., D.R. Senger, A.M. Dvorak, V.S. Harvey, and J. McDonagh. 1985. Regulation of extravascular coagulation by microvascular permeability. Science. 227:1059-1061. doi:10.1126/science.3975602
21. Ellerby, H.M., W. Arap, L.M. Ellerby, R. Kain, R. Andrusiak, G.D. Rio, S. Krajewski, C.R. Lombardo, R. Rao, E. Ruoslahti, et al. 1999. Anticancer activity of targeted pro-apoptotic peptides. Nat. Med. 5:1032-1038. doi:10.1038/12469
22. Erdreich-Epstein, A., H. Shimada, S. Groshen, M. Liu, L.S. Metelitsa, K.S. Kim, M.F. Stins, R.C. Seeger, and D.L. Durden. 2000. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 60:712-721.
23. Fogal, V., L. Zhang, S. Krajewski, and E. Ruoslahti. 2008. Mitochondrial/cellsurface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 68:7210-7218. doi:10.1158/0008-5472 .CAN-07-6752
24. Fogal, V., K.N. Sugahara, E. Ruoslahti, and S. Christian. 2009. Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Angiogenesis. 12:91-100. doi:10.1007/s10456-009- 9137-5
25. Gee, M.S., R. Upadhyay, H. Bergquist, H. Alencar, F. Reynolds, M. Maricevich, R. Weissleder, L. Josephson, and U. Mahmood. 2008. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology. 248:925-935. doi:10.1148/radiol. 2482071496
26. Gregorc, V., G. Citterio, G. Vitali, A. Spreafico, P. Scifo, A. Borri, G. Donadoni, G. Rossoni, A. Corti, F. Caligaris-Cappio, et al. 2010. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur. J. Cancer. 46:198-206. doi:10.1016/ j.ejca.2009.10.005
27. Gump, J.M., and S.F. Dowdy. 2007. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol. Med. 13:443-448. doi:10.1016/ j.molmed.2007.08.002
28. Hambley, T.W., and W.N. Hait. 2009. Is anticancer drug development heading in the right direction? Cancer Res. 69:1259-1262. doi:10.1158/0008-5472.CAN-08-3786
29. Hamzah, J., D. Nelson, G. Moldenhauer, B. Arnold, G.J. Hämmerling, and R. Ganss. 2008. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 118:1691-1699. doi:10.1172/JCI33201
30. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353-364. doi:10 .1016/S0092-8674(00)80108-7
31. Harris, T.J., G. von Maltzahn, M.E. Lord, J.H. Park, A. Agrawal, D.H. Min, M.J. Sailor, and S.N. Bhatia. 2008. Protease-triggered unveiling of bioactive nanoparticles. Small. 4:1307-1312. doi:10.1002/smll.200701319
32. Haviv, Y.S., J.L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, et al. 2002. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res. 62:4273-4281.
33. Heldin, C.H., K. Rubin, K. Pietras, and A. Ostman. 2004. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer. 4:806-813. doi:10.1038/nrc1456
34. Henke, E., J. Perk, J. Vider, P. de Candia, Y. Chin, D.B. Solit, V. Ponomarev, L. Cartegni, K. Manova, N. Rosen, and R. Benezra. 2008. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat. Biotechnol. 26:91-100. doi:10.1038/nbt1366
35. Hirsch, L.R., R.J. Stafford, J.A. Bankson, S.R. Sershen, B. Rivera, R.E. Price, J.D. Hazle, N.J. Halas, and J.L. West. 2003. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. USA. 100:13549-13554. doi:10.1073/pnas.2232479100
36. Hoffman, J.A., E. Giraudo, M. Singh, L. Zhang, M. Inoue, K. Porkka, D. Hanahan, and E. Ruoslahti. 2003. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell. 4:383-391. doi:10.1016/S1535-6108(03)00273-3
37. Hong, S., P.R. Leroueil, I.J. Majoros, B.G. Orr, J.R. Baker Jr., and M.M. Banaszak Holl. 2007. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem. Biol. 14:107-115. doi:10 .1016/j.chembiol.2006.11.015
38. Hood, J.D., M. Bednarski, R. Frausto, S. Guccione, R.A. Reisfeld, R. Xiang, and D.A. Cheresh. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2404-2407. doi:10.1126/science .1070200
39. Hu, M., J. Chen, Z.Y. Li, L. Au, G.V. Hartland, X. Li, M. Marquez, and Y. Xia. 2006. Gold nanostructures: engineering their plasmonic properties for biomedical applications. Chem. Soc. Rev. 35:1084-1094. doi:10.1039/ b517615h
40. Huang, X., G. Molema, S. King, L. Watkins, T.S. Edgington, and P.E. Thorpe. 1997. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:547-550. doi:10.1126/science .275.5299.547
41. Iyer, A.K., G. Khaled, J. Fang, and H. Maeda. 2006. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today. 11:812-818. doi:10.1016/j.drudis.2006.07.005
42. Jacobson, B.S., D.B. Stolz, and J.E. Schnitzer. 1996. Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nat. Med. 2:482-484. doi:10.1038/nm0496-482
43. Jain, R.K. 1999. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1:241-263. doi:10.1146/annurev.bioeng.1. 1.241
44. Järvinen, T.A., and E. Ruoslahti. 2007. Molecular changes in the vasculature of injured tissues. Am. J. Pathol. 171:702-711. doi:10.2353/ajpath .2007.061251
45. Jiang, T., E.S. Olson, Q.T. Nguyen, M. Roy, P.A. Jennings, and R.Y. Tsien. 2004. Tumor imaging by means of proteolytic activation of cellpenetrating peptides. Proc. Natl. Acad. Sci. USA. 101:17867-17872. doi:10.1073/pnas.0408191101
46. Joyce, J.A., P. Laakkonen, M. Bernasconi, G. Bergers, E. Ruoslahti, and D. Hanahan. 2003. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 4:393-403. doi:10.1016/S1535-6108(03)00271-X
47. Karmali, P.P., V.R. Kotamraju, M. Kastantin, M. Black, D. Missirlis, M. Tirrell, and E. Ruoslahti. 2009. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine. 5:73-82.
48. Karpanen, T., and K. Alitalo. 2008. Molecular biology and pathology of lymphangiogenesis. Annu. Rev. Pathol. 3:367-397. doi:10.1146/annurev .pathmechdis.3.121806.151515
49. Kelly, K.A., N. Bardeesy, R. Anbazhagan, S. Gurumurthy, J. Berger, H. Alencar, R.A. Depinho, U. Mahmood, and R. Weissleder. 2008. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 5:e85. doi:10.1371/journal.pmed.0050085
50. Kim, B.S., and T.A. Taton. 2007. Multicomponent nanoparticles via self-assembly with cross-linked block copolymer surfactants. Langmuir. 23:2198-2202. doi:10.1021/la062692w
51. Kim, H., M. Achermann, L.P. Balet, J.A. Hollingsworth, and V.I. Klimov. 2005. Synthesis and characterization of Co/CdSe core/shell nanocomposites: bifunctional magnetic-optical nanocrystals. J. Am. Chem. Soc. 127:544-546. doi:10.1021/ja047107x
52. Koivunen, E., B. Wang, and E. Ruoslahti. 1994. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J. Cell Biol. 124:373-380. doi:10.1083/jcb.124.3.373
53. Kranenborg, M.H., O.C. Boerman, J.C. Oosterwijk-Wakka, M.C. de Weijert, F.H. Corstens, and E. Oosterwijk. 1998. Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renalcell-carcinoma X anti-DTPA bispecific monoclonal antibodies. Int. J. Cancer. 75:74-80. doi:10.1002/(SICI)1097-0215(19980105)75:1<74:: AID-IJC12>3.0.CO;2-D
54. Laakkonen, P., K. Porkka, J.A. Hoffman, and E. Ruoslahti. 2002. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8:751-755.
55. Laakkonen, P., M.E. Akerman, H. Biliran, M. Yang, F. Ferrer, T. Karpanen, R.M. Hoffman, and E. Ruoslahti. 2004. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. USA. 101:9381-9386. doi:10.1073/pnas.0403317101
56. Lewis, V.O., M.G. Ozawa, M.T. Deavers, G. Wang, T. Shintani, W. Arap, and R. Pasqualini. 2009. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res. 69:1995-1999. doi:10.1158/0008-5472.CAN-08-4845
57. Maeda, H., J. Wu, T. Sawa, Y. Matsumura, and K. Hori. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 65:271-284. doi:10.1016/S0168-3659(99)00248- 5
58. Moghimi, S.M., A.C. Hunter, and J.C. Murray. 2001. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol. Rev. 53:283-318.
59. Montet, X., M. Funovics, K. Montet-Abou, R. Weissleder, and L. Josephson. 2006. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 49:6087-6093. doi:10.1021/jm060515m
60. Mueller, J., F.C. Gaertner, B. Blechert, K.P. Janssen, and M. Essler. 2009. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo. Mol. Cancer Res. 7:1078-1085. doi:10.1158/1541-7786.MCR-08-0538
61. Müller, O.J., F. Kaul, M.D. Weitzman, R. Pasqualini, W. Arap, J.A. Kleinschmidt, and M. Trepel. 2003. Random peptide libraries displayed on adenoassociated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21:1040-1046. doi:10.1038/nbt856
62. Murphy, E.A., B.K. Majeti, L.A. Barnes, M. Makale, S.M. Weis, K. Lutu-Fuga, W. Wrasidlo, and D.A. Cheresh. 2008. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. USA. 105:9343-9348. doi:10.1073/pnas.0803728105
63. Nanda, A., E.B. Carson-Walter, S. Seaman, T.D. Barber, J. Stampfl, S. Singh, B. Vogelstein, K.W. Kinzler, and B. St Croix. 2004. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res. 64:817-820. doi:10.1158/0008-5472.CAN-03-2408
64. Nilsson, F., H. Kosmehl, L. Zardi, and D. Neri. 2001. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 61:711-716.
65. Oh, P., Y. Li, J. Yu, E. Durr, K.M. Krasinska, L.A. Carver, J.E. Testa, and J.E. Schnitzer. 2004. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature. 429:629-635. doi:10.1038/nature02580
66. Olive, K.P., M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, et al. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 324:1457-1461. doi:10.1126/science. 1171362
67. Paoloni, M.C., A. Tandle, C. Mazcko, E. Hanna, S. Kachala, A. Leblanc, S. Newman, D. Vail, C. Henry, D. Thamm, et al. 2009. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One. 4:e4972. doi:10.1371/journal.pone.0004972
68. Park, J.H., G. von Maltzahn, E. Ruoslahti, S.N. Bhatia, and M.J. Sailor. 2008. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew. Chem. Int. Ed. Engl. 47:7284-7288. doi:10.1002/anie.200801810
69. Park, J.-H., L. Gu, G. von Maltzahn, E. Ruoslahti, S.N. Bhatia, and M.J. Sailor. 2009a. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat. Mater. 8:331-336. doi:10.1038/nmat2398
70. Park, J.-H., G. von Maltzahn, L. Zhang, A.M. Derfus, D. Simberg, T.J. Harris, E. Ruoslahti, S.N. Bhatia, and M.J. Sailor. 2009b. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small. 5:694-700. doi:10.1002/smll.200801789
71. Park, J.-H., G. von Maltzahn, M.J. Xu, V. Fogal, V.R. Kotamraju, E. Ruoslahti, S.N. Bhatia, and M.J. Sailor. 2010. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc. Natl. Acad. Sci. USA. 107:981-986. doi:10.1073/pnas.0909565107
72. Pasqualini, R., and E. Ruoslahti. 1996. Organ targeting in vivo using phage display peptide libraries. Nature. 380:364-366. doi:10.1038/380364a0
73. Pasqualini, R., E. Koivunen, R. Kain, J. Lahdenranta, M. Sakamoto, A. Stryhn, R.A. Ashmun, L.H. Shapiro, W. Arap, and E. Ruoslahti. 2000. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60:722-727.
74. Peer, D., J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2:751-760. doi:10.1038/nnano.2007.387
75. Pilch, J., D.M. Brown, M. Komatsu, T.A. Järvinen, M. Yang, D. Peters, R.M. Hoffman, and E. Ruoslahti. 2006. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc. Natl. Acad. Sci. USA. 103:2800-2804. doi:10.1073/pnas.0511219103
76. Porkka, K., P. Laakkonen, J.A. Hoffman, M. Bernasconi, and E. Ruoslahti. 2002. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA. 99:7444-7449. doi:10.1073/pnas.062189599
77. Rangel, R., Y. Sun, L. Guzman-Rojas, M.G. Ozawa, J. Sun, R.J. Giordano, C.S. Van Pelt, P.T. Tinkey, R.R. Behringer, R.L. Sidman, et al. 2007. Impaired angiogenesis in aminopeptidase N-null mice. Proc. Natl. Acad. Sci. USA. 104:4588-4593. doi:10.1073/pnas.0611653104
78. Reddy, G.R., M.S. Bhojani, P. McConville, J. Moody, B.A. Moffat, D.E. Hall, G. Kim, Y.E. Koo, M.J. Woolliscroft, J.V. Sugai, et al. 2006. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res. 12:6677-6686. doi:10.1158/1078-0432.CCR-06-0946
79. Reulen, S.W., P.Y. Dankers, P.H. Bomans, E.W. Meijer, and M. Merkx. 2009. Collagen targeting using protein-functionalized micelles: the strength of multiple weak interactions. J. Am. Chem. Soc. 131:7304-7312. doi:10 .1021/ja807723p
80. Roth, J.M., M. Caunt, A. Cretu, A. Akalu, D. Policarpio, X. Li, P. Gagne, S. Formenti, and P.C. Brooks. 2006. Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am. J. Pathol. 168:1576-1586. doi:10.2353/ajpath.2006.050176
81. Ruoslahti, E. 2002. Specialization of tumour vasculature. Nat. Rev. Cancer. 2:83-90. doi:10.1038/nrc724
82. Salazar, M.D., and M. Ratnam. 2007. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 26:141-152. doi:10.1007/s10555-007-9048-0
83. Sathe, T.R., A. Agrawal, and S. Nie. 2006. Mesoporous silica beads embedded with semiconductor quantum dots and iron oxide nanocrystals: dualfunction microcarriers for optical encoding and magnetic separation. Anal. Chem. 78:5627-5632. doi:10.1021/ac0610309
84. Seaman, S., J. Stevens, M.Y. Yang, D. Logsdon, C. Graff-Cherry, and B. St Croix. 2007. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 11:539-554. doi:10.1016/j.ccr.2007.04.017
85. Sharkey, R.M., and D.M. Goldenberg. 2005. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46(Suppl 1): 115S-127S.
86. Simberg, D., T. Duza, J.H. Park, M. Essler, J. Pilch, L. Zhang, A.M. Derfus, M. Yang, R.M. Hoffman, S. Bhatia, et al. 2007. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA. 104:932-936. doi:10.1073/pnas.0610298104
87. Simberg, D., J.-H. Park, P.P. Karmali, W.-M. Zhang, S. Merkulov, K. McCrae, S.N. Bhatia, M. Sailor, and E. Ruoslahti. 2009. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials. 30:3926-3933. doi:10.1016/j.biomaterials.2009.03.056
88. Sipkins, D.A., D.A. Cheresh, M.R. Kazemi, L.M. Nevin, M.D. Bednarski, and K.C. Li. 1998. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. 4:623-626. doi:10.1038/nm0598-623
89. Song, S., A.J. Ewald, W. Stallcup, Z. Werb, and G. Bergers. 2005. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7:870-879. doi:10.1038/ncb1288
90. Song, E.Q., G.P. Wang, H.Y. Xie, Z.L. Zhang, J. Hu, J. Peng, D.C. Wu, Y.B. Shi, and D.W. Pang. 2007. Visual recognition and efficient isolation of apoptotic cells with fluorescent-magnetic-biotargeting multifunctional nanospheres. Clin. Chem. 53:2177-2185. doi:10.1373/clinchem.2007.092023
91. Stallcup, W.B., and F.J. Huang. 2008. A role for the NG2 proteoglycan in glioma progression. Cell Adh Migr. 2:192-201.
92. Stollman, T.H., T.J. Ruers, W.J. Oyen, and O.C. Boerman. 2009. New targeted probes for radioimaging of angiogenesis. Methods. 48:188-192. doi:10.1016/j.ymeth.2009.03.006
93. Sugahara, K.N., T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, O.M. Girard, D. Hanahan, R.F. Mattrey, and E. Ruoslahti. 2009. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 16:510-520. doi:10.1016/j.ccr.2009.10.013
94. Teesalu, T., K.N. Sugahara, V.R. Kotamraju, and E. Ruoslahti. 2009. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. USA. 106:16157-16162. doi:10.1073/ pnas.0908201106
95. Thurber, G.M., M.M. Schmidt, and K.D. Wittrup. 2008. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60:1421-1434. doi:10.1016/j.addr.2008.04.012
96. van Osdol, W., K. Fujimori, and J.N. Weinstein. 1991. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res. 51:4776-4784.
97. von Maltzahn, G., A. Centrone, J.-H. Park, R. Ramanathan, M.J. Sailor, T.A. Hatton, and S.N. Bhatia. 2009. SERS-coded gold nanorods as a multifunctional platform for densely multiplexed near-infrared imaging and photothermal heating. Adv. Mater. 21:3175-3180. doi:10 .1002/adma.200803464
98. 3 beads-CdSe/ZnS quantum dots core-shell nanocomposite particles for cell separation. Nano Lett. 4:409-413. doi:10.1021/nl035010n
99. Wickham, T.J. 2000. Targeting adenovirus. Gene Ther. 7:110-114. doi:10.1038/ sj.gt.3301115
100. Xu, J., D. Rodriguez, E. Petitclerc, J.J. Kim, M. Hangai, Y.S. Moon, G.E. Davis, P.C. Brooks, and S.M. Yuen. 2001. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154:1069-1079. doi:10.1083/jcb.200103111
101. Ye, F., X. Wu, E.K. Jeong, Z. Jia, T. Yang, D. Parker, and Z.R. Lu. 2008. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug. Chem. 19:2300-2303. doi:10.1021/bc800211r